CAR T-cell therapy for B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: clinical trials and real-world experiences
C Vitale, P Strati - Frontiers in oncology, 2020 - frontiersin.org
Chimeric antigen receptor-modified (CAR) T cells targeting CD19 have revolutionized the
treatment of relapsed or refractory aggressive B-cell lymphomas, and their use has …
treatment of relapsed or refractory aggressive B-cell lymphomas, and their use has …
[HTML][HTML] Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
GD Myers, MR Verneris, A Goy… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) T-cell therapies that specifically target the CD19 antigen
have emerged as a highly effective treatment option in patients with refractory B-cell …
have emerged as a highly effective treatment option in patients with refractory B-cell …
[HTML][HTML] The International Prognostic Index is associated with outcomes in diffuse large B cell lymphoma after chimeric antigen receptor T cell therapy
M Garcia-Recio, K Wudhikarn, M Pennisi… - … and cellular therapy, 2021 - Elsevier
ABSTRACT CD19-targeted chimeric antigen receptor (CAR) T cells have shown excellent
activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T …
activity against relapsed and refractory (R/R) diffuse large B cell lymphoma (DLBCL). CAR T …
Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials
F Yassine, M Iqbal, H Murthy… - Current Research in …, 2020 - Elsevier
Advances in the field of immuno-oncology brought chimeric antigen receptor T (CAR T) cell
therapy from the bench to the bedside for treatment of relapsed and/or refractory B-cell …
therapy from the bench to the bedside for treatment of relapsed and/or refractory B-cell …
[HTML][HTML] Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic …
P Dreger, TS Fenske, S Montoto, MC Pasquini… - Biology of Blood and …, 2020 - Elsevier
Chimeric antigen receptor-engineered T (CART) cells are a promising new treatment option
for patients with multiply relapsed and refractory (R/R) diffuse large B cell lymphoma …
for patients with multiply relapsed and refractory (R/R) diffuse large B cell lymphoma …
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysis
Data on real-world outcomes of axicabtagene ciloleucel (axi-cel) therapy for
relapsed/refractory large B-cell lymphoma (R/R LBCL) are limited. In this intent to treat (ITT) …
relapsed/refractory large B-cell lymphoma (R/R LBCL) are limited. In this intent to treat (ITT) …
[HTML][HTML] Impact of a multidisciplinary nutritional support team on quality improvement for patients receiving home parenteral nutrition
M Rothkopf, M Pant, R Brown, J Haselhorst… - … , Prevention & Health, 2022 - ncbi.nlm.nih.gov
Objective To determine an MNST effect on adherence to protocols, outcomes and quality of
life (QOL) in HPN. Methods The study was divided into three phases: data review (phases …
life (QOL) in HPN. Methods The study was divided into three phases: data review (phases …
[HTML][HTML] Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation?
P Dreger, TS Fenske, S Montoto… - Biology of blood and …, 2020 - ncbi.nlm.nih.gov
Chimeric antigen receptor-engineered T (CART) cells are a promising new treatment option
for patients with multiply relapsed and refractory (R/R) diffuse large B-cell lymphoma …
for patients with multiply relapsed and refractory (R/R) diffuse large B-cell lymphoma …